Nicola J Nasser1, Victoria Chernyak2, Viswanathan Shankar3, Madhur Garg1, William Bodner1, Shalom Kalnicki1, Jonathan Klein1. 1. Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, United States. 2. Department of Radiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, United States. 3. Department of Epidemiology & Population Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, United States.
Abstract
INTRODUCTION: Radical prostatectomy (RP) is a standard treatment modality for localized prostate cancer. Biochemical failure after RP is usually evaluated with whole-body imaging to exclude distant metastatic disease, and pelvic magnetic resonance imaging (MRI) to detect local recurrence in the prostatectomy bed. The goal of this study is to correlate disease characteristics and demographic data in patients with rising prostate-specific antigen (PSA) after RP to determine association with MRI-detected cancer recurrence. METHODS: Sixty-four patients who underwent pelvic MRI for rising PSA after RP and had complete clinical and pathological data available were included. Using Chi-squared testing, we analyzed PSA levels, pathological disease characteristics (prostate cancer risk group, Gleason score, extracapsular extension, positive surgical margin, seminal vesicle involvement, perineural invasion, lymphovascular invasion, and PSA level before MRI), time from surgery to biochemical failure, and patient demographic characteristics as potential predictors of MRI-detected local recurrence. RESULTS: Definite MRI-detected local recurrence was observed in 17/64 patients (27%). Eleven (17%) patients had a suspicious lesion with the differential of scarring, retained seminal vesicle, or recurrent cancer. Thirty-six (56%) patients had no evidence of tumor in the prostate bed or pelvis on MRI. Patient race was associated with likelihood of detecting a prostate nodule on MRI (p=0.04), with African American patients having 82% lower odds of MRI-detected tumor recurrence compared with white patients (p=0.045). No other tumor or patient characteristic was significantly associated with MRI-detected recurrence. CONCLUSIONS: African American patients with biochemical failure after RP are less likely to have MRI-detectable recurrence in the prostate bed compared with white patients.
INTRODUCTION: Radical prostatectomy (RP) is a standard treatment modality for localized prostate cancer. Biochemical failure after RP is usually evaluated with whole-body imaging to exclude distant metastatic disease, and pelvic magnetic resonance imaging (MRI) to detect local recurrence in the prostatectomy bed. The goal of this study is to correlate disease characteristics and demographic data in patients with rising prostate-specific antigen (PSA) after RP to determine association with MRI-detected cancer recurrence. METHODS: Sixty-four patients who underwent pelvic MRI for rising PSA after RP and had complete clinical and pathological data available were included. Using Chi-squared testing, we analyzed PSA levels, pathological disease characteristics (prostate cancer risk group, Gleason score, extracapsular extension, positive surgical margin, seminal vesicle involvement, perineural invasion, lymphovascular invasion, and PSA level before MRI), time from surgery to biochemical failure, and patient demographic characteristics as potential predictors of MRI-detected local recurrence. RESULTS: Definite MRI-detected local recurrence was observed in 17/64 patients (27%). Eleven (17%) patients had a suspicious lesion with the differential of scarring, retained seminal vesicle, or recurrent cancer. Thirty-six (56%) patients had no evidence of tumor in the prostate bed or pelvis on MRI. Patient race was associated with likelihood of detecting a prostate nodule on MRI (p=0.04), with African American patients having 82% lower odds of MRI-detected tumor recurrence compared with white patients (p=0.045). No other tumor or patient characteristic was significantly associated with MRI-detected recurrence. CONCLUSIONS: African American patients with biochemical failure after RP are less likely to have MRI-detectable recurrence in the prostate bed compared with white patients.
Authors: Francesco Ceci; Ken Herrmann; Paolo Castellucci; Tiziano Graziani; Christina Bluemel; Riccardo Schiavina; Christian Vollmer; Sabine Droll; Eugenio Brunocilla; Renzo Mazzarotto; Andreas K Buck; Stefano Fanti Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-15 Impact factor: 9.236
Authors: Maria Thor; Andrew Jackson; Michael J Zelefsky; Gunnar Steineck; Asa Karlsdòttir; Morten Høyer; Mitchell Liu; Nicola J Nasser; Stine E Petersen; Vitali Moiseenko; Joseph O Deasy Journal: Radiother Oncol Date: 2018-03-09 Impact factor: 6.280
Authors: Stanley L Liauw; Sean P Pitroda; Scott E Eggener; Walter M Stadler; Charles A Pelizzari; Michael W Vannier; Aytek Oto Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-18 Impact factor: 7.038
Authors: Adam T Froemming; Sadhna Verma; Steven C Eberhardt; Aytekin Oto; Lauren F Alexander; Brian C Allen; Fergus V Coakley; Brian J Davis; Pat F Fulgham; Keyanoosh Hosseinzadeh; Christopher Porter; V Anik Sahni; David M Schuster; Timothy N Showalter; Aradhana M Venkatesan; Carolyn L Wang; Erick M Remer Journal: J Am Coll Radiol Date: 2018-05 Impact factor: 5.532
Authors: Kazuhiro Kitajima; Robert C Murphy; Mark A Nathan; Adam T Froemming; Clinton E Hagen; Naoki Takahashi; Akira Kawashima Journal: J Nucl Med Date: 2014-01-16 Impact factor: 10.057
Authors: Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young Journal: Lancet Oncol Date: 2008-07-17 Impact factor: 41.316
Authors: D Hernandez; D Salas; D Giménez; P Buitrago; S Esquena; J Palou; P de la Torre; J Pernas; I Gich; G Gómez de Segura; J Craven-Bartle; G Sancho Journal: Radiat Oncol Date: 2015-12-24 Impact factor: 3.481